12:00 AM
Jul 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Resten-NG: Began Phase I testing

(Research news, B13)

AVI Biopharma Inc. (AVII), Portland, Ore.
Product: Resten-NG
Business: Cardiovascular
Therapeutic category: Antisense
Target: c-myc

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >